Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Dec 21;21(47):13400-2.
doi: 10.3748/wjg.v21.i47.13400.

Current status of superparamagnetic iron oxide contrast agents for liver magnetic resonance imaging

Yi-Xiang J Wang  1
Affiliations
Comment

Current status of superparamagnetic iron oxide contrast agents for liver magnetic resonance imaging

Yi-Xiang J Wang. World J Gastroenterol. .

Abstract

Five types of superparamagnetic iron oxide (SPIO), i.e. Ferumoxides (Feridex(®) IV, Berlex Laboratories), Ferucarbotran (Resovist(®), Bayer Healthcare), Ferumoxtran-10 (AMI-227 or Code-7227, Combidex(®), AMAG Pharma; Sinerem(®), Guerbet), NC100150 (Clariscan(®), Nycomed,) and (VSOP C184, Ferropharm) have been designed and clinically tested as magnetic resonance contrast agents. However, until now Resovist(®) is current available in only a few countries. The other four agents have been stopped for further development or withdrawn from the market. Another SPIO agent Ferumoxytol (Feraheme(®)) is approved for the treatment of iron deficiency in adult chronic kidney disease patients. Ferumoxytol is comprised of iron oxide particles surrounded by a carbohydrate coat, and it is being explored as a potential imaging approach for evaluating lymph nodes and certain liver tumors.

Keywords: Eovist; Gd-EOB-DTPA; Hepatocellular carcinoma; Liver; Magnetic resonance imaging; Primovist; Resovist; Superparamagnetic iron oxide.

PubMed Disclaimer

Comment on

References

    1. Li YW, Chen ZG, Wang JC, Zhang ZM. Superparamagnetic iron oxide-enhanced magnetic resonance imaging for focal hepatic lesions: systematic review and meta-analysis. World J Gastroenterol. 2015;21:4334–4344. - PMC - PubMed
    1. Corot C, Robert P, Idée JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev. 2006;58:1471–1504. - PubMed
    1. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001;11:2319–2331. - PubMed
    1. Wang YX. Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application. Quant Imaging Med Surg. 2011;1:35–40. - PMC - PubMed
    1. Klein C, Nagel E, Schnackenburg B, Bornstedt A, Schalla S, Hoffmann V, Lehning A, Fleck E. The intravascular contrast agent Clariscan (NC 100150 injection) for 3D MR coronary angiography in patients with coronary artery disease. MAGMA. 2000;11:65–67. - PubMed